Investigating how specific autoantibodies contribute to chronic pain signaling
Anti-CV2 autoantibodies unmask a CRMP5/GluN2B pain signaling hub
['FUNDING_R01'] · SAINT LOUIS UNIVERSITY · NIH-10756463
This study is looking at how certain antibodies in the body might affect nerve pain, especially in older adults, to help find better treatments for people dealing with chronic pain.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SAINT LOUIS UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10756463 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of anti-CV2 autoantibodies in neuropathic pain, a condition that affects a significant portion of the population, especially as they age. By analyzing patient samples, the study aims to uncover how these autoantibodies interact with a protein called CRMP5, which is involved in pain signaling. The researchers will explore the neuroimmune interactions that contribute to abnormal pain states, with the goal of developing more effective and targeted therapies for neuropathic pain. This approach seeks to bridge the gap between basic science and clinical application, potentially leading to better treatment options for patients suffering from chronic pain.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who suffer from neuropathic pain, particularly those with associated autoantibodies.
Not a fit: Patients who do not experience neuropathic pain or are under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new, more effective treatments for neuropathic pain that minimize side effects.
How similar studies have performed: While the role of autoantibodies in pain signaling is an emerging area of research, this specific approach targeting CRMP5 is relatively novel and has not been extensively tested.
Where this research is happening
SAINT LOUIS, UNITED STATES
- SAINT LOUIS UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MOUTAL, AUBIN — SAINT LOUIS UNIVERSITY
- Study coordinator: MOUTAL, AUBIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.